Question 1

How does reimbursement work in Japan?

Accepted Answer

Japan operates a national health insurance system, and many prescription drugs, medical devices and procedures require listing or coverage under the relevant reimbursement framework. The route depends on the product category, evidence, clinical value and comparator products. Regulatory approval does not itself guarantee favorable reimbursement pricing or adoption. Companies should assess this early and align regulatory evidence, pricing assumptions and launch preparation.

Question 2

Why is reimbursement planning important before Japan launch?

Accepted Answer

Reimbursement planning is important because approval alone does not define the commercial opportunity. Companies should understand the pricing of relevant comparators, evidence requirements for premium pricing and their likely pricing outcome before choosing a launch model. Early assessment may influence clinical evidence plans, partner discussions and investment decisions. It also helps determine whether the expected Japan opportunity is commercially realistic.

Question 3

Can innovative products receive reimbursement in Japan?

Accepted Answer

Yes. Innovative products receive reimbursement in Japan when they meet the relevant requirements and demonstrate value within the applicable framework. The outcome depends on the product category, comparators, strength of clinical evidence and the unmet need. Innovation alone does not guarantee coverage or favorable pricing. The clinical and economic value case should be supported by evidence relevant to Japanese patients and healthcare practice, and support from influential doctors is critical.

Question 4

How are drug prices determined in Japan?

Accepted Answer

New drug prices in Japan are calculated using a comparison method when an appropriate comparator drug exists, or a cost-based accounting method when one does not. Adjustments may reflect clinical usefulness, innovation, market characteristics and timeliness of Japan submission. The applicable method and resulting price depend on the product and evidence package. Companies should test realistic pricing assumptions early because they will affect partner interest, investment and launch strategy.

Question 5

What market access questions should companies ask before entering Japan?

Accepted Answer

Companies should ask whether the product addresses a clear need in Japan, which reimbursement route may apply, what evidence supports value, how it compares with current care, what pricing is realistic, and how patients will receive treatment. They should also identify the stakeholders who influence adoption. These questions should be assessed early before finalizing development, partnering or launch plans.

Question 6

Why should regulatory and market access planning be connected?

Accepted Answer

Regulatory and market access planning should be connected because the evidence supporting approval also affects reimbursement pricing and adoption. An approvable indication or study design may not create the strongest commercial position. Companies should assess whether endpoints, comparators, patient population, local evidence and timing support both regulatory review and post-approval access. This can prevent costly gaps between approval strategy and market needs.

Question 7

What does commercial readiness mean in Japan?

Accepted Answer

Commercial readiness means having the local structure, partner model, supply and distribution plan, compliance processes, medical affairs approach, price listing and stakeholder engagement needed for launch. It also requires clear responsibilities, budgets and decision-making. For foreign companies, readiness often depends on practical local execution rather than strategy alone. The required capabilities vary by product, launch ambition and market entry model.

FAQ